FOSUN PHARMA announced that it would provide guarantees for several holding subsidiaries, totaling over 1.7 billion RMB. This guarantee involves multiple subsidiaries including FOSUN PHARMA industry, FOSUN Industrial, FOSUN Antking, FOSUN Yalifeng, and Hanlin Medical Trade, aimed at supporting their daily operations' required loans and credit limits.The scope of the guarantees includes a credit limit of 300 million RMB for FOSUN PHARMA industry, 35 million USD and 140 million RMB in loans for FOSUN Industrial, 100 million RMB in loans for FOSUN Antking, 60 million RMB in credit limits for FOSUN Yalifeng, and 10 million RMB in loans for Hanlin Medical Trade. The company stated that these guarantees are all within the limits approved by the Shareholders' Meeting, with controllable risks, and are necessary and reasonable.Show More

FOSUN PHARMA announced that it would provide guarantees for several holding subsidiaries, totaling over 1.7 billion RMB. This guarantee involves multiple subsidiaries including FOSUN PHARMA industry, FOSUN Industrial, FOSUN Antking, FOSUN Yalifeng, and Hanlin Medical Trade, aimed at supporting their daily operations' required loans and credit limits.The scope of the guarantees includes a credit limit of 300 million RMB for FOSUN PHARMA industry, 35 million USD and 140 million RMB in loans for FOSUN Industrial, 100 million RMB in loans for FOSUN Antking, 60 million RMB in credit limits for FOSUN Yalifeng, and 10 million RMB in loans for Hanlin Medical Trade. The company stated that these guarantees are all within the limits approved by the Shareholders' Meeting, with controllable risks, and are necessary and reasonable.As of December 23, 2024, FOSUN PHARMA Group's actual external guarantee amount is approximately 31.907 billion RMB, accounting for 69.84% of the net assets attributable to the listed company's Shareholders at the end of 2023. The company emphasizes that all guarantees are made between it and its holding subsidiaries, and there are currently no overdue guarantee matters.